Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Blood

• Publication date

  1998-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V92.1.168.413K06_168_174PMID 9639513
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regional localization of the human factor IX gene by molecular hybridization

  2004cited by this paper
• Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX.

  1997cited by this paper
• Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

  1997cited by this paper
• Capture and Expansion of Bone Marrow-Derived Mesenchymal Progenitor Cells with a Transforming Growth Factor-β1–von Willebrand's Factor Fusion Protein for Retrovirus-Mediated Delivery of Coagulation Factor IX

  1997cited by this paper
• A coagulation factor IX-deficient mouse model for human hemophilia B.

  1997cited by this paper
• A factor IX-deficient mouse model for hemophilia B gene therapy.

  1997cited by this paper
• Comparison of Retroviral and Adeno-Associated Viral Vectors Designed to Express Human Clotting Factor IX

  1997cited by this paper
• Haemophilia B (sixth edition): a database of point mutations and short additions and deletions

  1996cited by this paper
• Age and Sex Dependent Regulation of the Factor IX Gene in Mice

  1996cited by this paper
• Construction of Human Factor IX Expression Vectors in Retroviral Vector Frames Optimized for Muscle Cells

  1996cited by this paper
• Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression

  1995cited by this paper
• Expression of Biologically Active Human Factor IX in Human Hematopoietic Cells after Retroviral Vector-Mediated Gene Transduction

  1995cited by this paper
• Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

  1995cited by this paper
• Gene therapy and the hemophilias.

  1994cited by this paper
• Isolation, culture, and manipulation of embryonic stem cells

  1994cited by this paper
• Current therapeutic relevance of liver gene transfer

  1994cited by this paper
• In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

  1994cited by this paper
• Towards gene therapy for haemophilia B using primary human keratinocytes

  1993cited by this paper
• Molecular Biology of Hemophilia B

  1993cited by this paper
• Gene targeting in embryonic stem cells.

  1993cited by this paper
• The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene

  1993cited by this paper
• Lack of N regions in antigen receptor variable region genes of TdT-deficient lymphocytes.

  1993cited by this paper
• In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.

  1993cited by this paper
• Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice

  1993cited by this paper
• Expression of coagulation factor IX (Christmas factor) in human hepatoma (HepG2) cell cultures after retroviral vector-mediated transfer.

  1993cited by this paper
• Biology of factor IX.

  1992cited by this paper
• Expression of human factor IX in mice after injection of genetically modified myoblasts.

  1992cited by this paper
• Production of homozygous mutant ES cells with a single targeting construct

  1992cited by this paper
• Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants.

  1991cited by this paper
• Characterization of a Mouse Factor IX cDNA and Developmental Regulation of the Factor IX Gene Expression in Liver

  1991cited by this paper
• Why does the human factor IX gene have a G + C content of 40%?

  1991cited by this paper
• Gene targeting in embryonic stem cells.

  1991cited by this paper
• Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes

  1988cited by this paper
• Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells.

  1987cited by this paper
• Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

  1985cited by this paper

• Animal Models of Hemophilia B (A Review)

  2025cites this paper
• Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

  2024cites this paper
• Gene therapy for hemophilia.

  2022cites this paper
• Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)

  2021cites this paper
• Mouse models of hemostasis

  2020cites this paper
• Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs

  2019cites this paper
• Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?

  2019cites this paper
• Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis

  2018cites this paper
• Advances in Gene Therapy for Hemophilia

  2017cites this paper
• Gene Therapy for Hemophilia.

  2017cites this paper
• Toward Personalized Gene Therapy: Characterizing the Host Genetic Control of Lentiviral-Vector-Mediated Hepatic Gene Delivery

  2017cites this paper
• Severe Hemophilia A in a Male Old English Sheep Dog with a C→T Transition that Created a Premature Stop Codon in Factor VIII.

  2016cites this paper
• Current animal models of hemophilia: the state of the art

  2016cites this paper
• Treating Hemophilia by Gene Therapy

  2016cites this paper
• Haemophilia gene therapy: Progress and challenges.

  2015cites this paper
• Experienced U.S. Board Certified Pediatric Hematologist-Oncologist, cancer drug developer, biopharmaceutical founder and executive with a proven track record in translational biomedical research, patient care and cancer drug development, from Phase I-IV NIH-FDA and Industry-sponsored clinical trials

  2015cites this paper
• Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow

  2015cites this paper
• Liver-Specific γ-Glutamyl Carboxylase-Deficient Mice Display Bleeding Diathesis and Short Life Span

  2014cites this paper
• Animal models of hemophilia and related bleeding disorders.

  2013cites this paper
• Blood Constituents and Safety Pharmacology 11

  2013cites this paper
• Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia.

  2012cites this paper
• Gene therapy for haemophilia B

  2012cites this paper
• Animal models of hemophilia.

  2012cites this paper
• Animal models of human genetic diseases: do they need to be faithful to be useful?

  2011cites this paper
• Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

  2011cites this paper
• In vivo models for the evaluation of antithrombotics and thrombolytics.

  2010cites this paper
• Vitamin-K-abhängige Gerinnungsfaktoren

  2010cites this paper
• Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?

  2009cites this paper
• Factor IX: Insights from knock-out and genetically engineered mice

  2008cites this paper
• In vivo models of haemophilia – status on current knowledge of clinical phenotypes and therapeutic interventions

  2008cites this paper
• THROMBIN REGULATION IN NEWBORN INFANTS

  2007cites this paper
• Pharmacological Assays in Thrombosis and Haemostasis

  2007cites this paper
• 10 – Artificial cells as a novel approach to gene therapy

  2007cites this paper
• Safety Pharmacology of Blood Constituents

  2006cites this paper
• Hemophilia as a Model Disease for Gene Therapy of Genetic Disorders

  2006cites this paper
• The promise and challenges of bioengineered recombinant clotting factors

  2005cites this paper
• Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases

  2005cites this paper
• Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis.

  2005cites this paper
• Protease nexin-2/amyloid β-protein precursor limits cerebral thrombosis

  2005cites this paper
• Testing novel hemophilia therapies: of mice and men

  2004cites this paper
• Coagulation and Fibrinolysis in Genetically Modified Mice

  2004cites this paper
• Gene Targeting of Tissue Factor, Factor X, and Factor VII in Mice: Their Involvement in Embryonic Development

  2004cites this paper
• Creation of a mouse expressing defective human factor IX.

  2004cites this paper
• Technical Assessment of the First 20 Years of Research Using Mouse Embryonic Stem Cell Lines

  2004cites this paper
• Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.

  2004cites this paper
• Preclinical animal models for hemophilia gene therapy: predictive value and limitations.

  2004cites this paper
• Preclinical Animal Models for Hemophilia Gene Therapy: Predictive Value and Limitations

  2004cites this paper
• Preclinical Gene Therapy Studies for Hemophilia Using Adenoviral Vectors

  2004cites this paper
• Preclinical gene therapy studies for hemophilia using adenoviral vectors.

  2004cites this paper
• Onco-Retroviral and Lentiviral Vector-Based Gene Therapy for Hemophilia: Preclinical Studies

  2004cites this paper
• Gene therapy of the hemophilias.

  2004cites this paper
• Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.

  2004cites this paper
• What is all that thrombin for?

  2003cites this paper
• The dynamics of thrombin formation.

  2003cites this paper
• Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX.

  2003cites this paper
• Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.

  2003cites this paper
• Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets.

  2003cites this paper
• Gene Transfer as an Approach to Treating Hemophilia

  2003cites this paper
• AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

  2003cites this paper
• Bone marrow stromal cells as a genetic platformfor systemic delivery of therapeutic proteins in vivo: human factor IX model

  2003cites this paper
• Myocardial Fibrosis in Mice Myocardial Fibrosis in Mice with Over-Expression of Human Blood Coagulation Factor IX by

  2002cites this paper
• Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics.

  2002cites this paper
• Gene targeting in hemostasis. Factor X.

  2002cites this paper
• AAV-mediated gene transfer for hemophilia

  2002cites this paper
• Gene Therapy of Hemophilia

  2001cites this paper
• Gene transfer as an approach to treating hemophilia.

  2001cites this paper
• AAV‐Mediated Gene Transfer for Hemophilia

  2001cites this paper
• Gene therapy: a 2001 perspective

  2001cites this paper
• Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi.

  2001cites this paper
• Gene therapy for hemophilia

  2001cites this paper
• Structural Investigations of Coagulation Factors

  2001cites this paper
• Thérapie génique appliquée à l'hémophilie

  2001cites this paper
• Genetic Interactions between the Coagulation and Fibrinolytic Systems

  2001cites this paper
• Gene Transfer as an Approach to Treating Hemophilia

  2001cites this paper
• Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis

  2001cites this paper
• Gene Therapy for Hemophilia

  2000cites this paper
• Blood Coagulation Factor X Deficiency Causes Partial Embryonic Lethality and Fatal Neonatal Bleeding in Mice

  2000cites this paper
• Rescue of Fatal Neonatal Hemorrhage in Factor V Deficient Mice by Low Level Transgene Expression

  2000cites this paper
• Blood coagulation.

  2000cites this paper
• Early Embryonic Expression of Murine Coagulation System Components

  2000cites this paper
• Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer

  1999cites this paper
• Gene therapy for hemophilia.

  1999cites this paper
• Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

  1999cites this paper
• Two Distinct Mutations Cause Severe Hemophilia B in Two Unrelated Canine Pedigrees

  1999cites this paper
• Gene therapy for the hemophilias.

  1999cites this paper
• "Normal" thrombin generation.

  1999cites this paper
• Gene therapy for the hemophilias.

  1999cites this paper
• Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.

  1999cites this paper
• Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B

  1999cites this paper
• Activity on blood constituents

  1997cites this paper